Pembrolizumab (Keytruda) has emerged as an effective frontline treatment option for select patients with metastatic non–small cell lung cancer, showing an overall survival advantage across 3 phase III clinical trials.
Original Article: Thoracic Oncologist Highlights Recent Pembrolizumab Data in NSCLC